First Time Loading...

Neurobo Pharmaceuticals Inc
NASDAQ:NRBO

Watchlist Manager
Neurobo Pharmaceuticals Inc Logo
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
Watchlist
Price: 3.45 USD 0.29%
Updated: Apr 19, 2024

Intrinsic Value

NRBO doesn't have a meaningful market cap.
NRBO's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. [ Read More ]

The intrinsic value of one NRBO stock under the Base Case scenario is 4.57 USD. Compared to the current market price of 3.45 USD, Neurobo Pharmaceuticals Inc is Undervalued by 25%.

Key Points:
NRBO Intrinsic Value
Base Case
4.57 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Neurobo Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NRBO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Neurobo Pharmaceuticals Inc

Provide an overview of the primary business activities
of Neurobo Pharmaceuticals Inc.

What unique competitive advantages
does Neurobo Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Neurobo Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Neurobo Pharmaceuticals Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neurobo Pharmaceuticals Inc.

Provide P/S
for Neurobo Pharmaceuticals Inc.

Provide P/E
for Neurobo Pharmaceuticals Inc.

Provide P/OCF
for Neurobo Pharmaceuticals Inc.

Provide P/FCFE
for Neurobo Pharmaceuticals Inc.

Provide P/B
for Neurobo Pharmaceuticals Inc.

Provide EV/S
for Neurobo Pharmaceuticals Inc.

Provide EV/GP
for Neurobo Pharmaceuticals Inc.

Provide EV/EBITDA
for Neurobo Pharmaceuticals Inc.

Provide EV/EBIT
for Neurobo Pharmaceuticals Inc.

Provide EV/OCF
for Neurobo Pharmaceuticals Inc.

Provide EV/FCFF
for Neurobo Pharmaceuticals Inc.

Provide EV/IC
for Neurobo Pharmaceuticals Inc.

Show me price targets
for Neurobo Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Neurobo Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Neurobo Pharmaceuticals Inc?

What are the Net Income projections
for Neurobo Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Neurobo Pharmaceuticals Inc?

What are the EPS projections
for Neurobo Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Neurobo Pharmaceuticals Inc?

What are the EBIT projections
for Neurobo Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Neurobo Pharmaceuticals Inc?

Compare the revenue forecasts
for Neurobo Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neurobo Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neurobo Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neurobo Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Neurobo Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Neurobo Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Neurobo Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Neurobo Pharmaceuticals Inc.

Provide ROE
for Neurobo Pharmaceuticals Inc.

Provide ROA
for Neurobo Pharmaceuticals Inc.

Provide ROIC
for Neurobo Pharmaceuticals Inc.

Provide ROCE
for Neurobo Pharmaceuticals Inc.

Provide Gross Margin
for Neurobo Pharmaceuticals Inc.

Provide Operating Margin
for Neurobo Pharmaceuticals Inc.

Provide Net Margin
for Neurobo Pharmaceuticals Inc.

Provide FCF Margin
for Neurobo Pharmaceuticals Inc.

Show all solvency ratios
for Neurobo Pharmaceuticals Inc.

Provide D/E Ratio
for Neurobo Pharmaceuticals Inc.

Provide D/A Ratio
for Neurobo Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Neurobo Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Neurobo Pharmaceuticals Inc.

Provide Quick Ratio
for Neurobo Pharmaceuticals Inc.

Provide Current Ratio
for Neurobo Pharmaceuticals Inc.

Provide Cash Ratio
for Neurobo Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Neurobo Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Neurobo Pharmaceuticals Inc?

What is the current Free Cash Flow
of Neurobo Pharmaceuticals Inc?

Financials

Balance Sheet Decomposition
Neurobo Pharmaceuticals Inc

Current Assets 22.5m
Cash & Short-Term Investments 22.4m
Other Current Assets 77k
Non-Current Assets 269k
PP&E 248k
Other Non-Current Assets 21k
Current Liabilities 6m
Accounts Payable 821k
Accrued Liabilities 4.5m
Other Current Liabilities 658k
Non-Current Liabilities 136k
Other Non-Current Liabilities 136k
Efficiency

Earnings Waterfall
Neurobo Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-15.9m USD
Operating Income
-15.9m USD
Other Expenses
3.4m USD
Net Income
-12.5m USD

Free Cash Flow Analysis
Neurobo Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NRBO Profitability Score
Profitability Due Diligence

Neurobo Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

37/100
Profitability
Score

Neurobo Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

NRBO Solvency Score
Solvency Due Diligence

Neurobo Pharmaceuticals Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Neurobo Pharmaceuticals Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NRBO Price Targets Summary
Neurobo Pharmaceuticals Inc

There are no price targets for NRBO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NRBO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NRBO Price
Neurobo Pharmaceuticals Inc

1M 1M
-16%
6M 6M
-1%
1Y 1Y
-38%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
3.45
52w Low
3.04
52w High
6.52
Price Metrics
Average Annual Return -69.78%
Standard Deviation of Annual Returns 29.33%
Max Drawdown -100%
Shares Statistics
Market Capitalization 16.9m USD
Shares Outstanding 4 906 030
Percentage of Shares Shorted 2.98%

NRBO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Neurobo Pharmaceuticals Inc Logo
Neurobo Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

16.9m USD

Dividend Yield

0%

Description

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in the development and commercialization of therapeutics. The company is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.

Contact

MASSACHUSETTS
Boston
200 Berkeley St., Fl 19
+18577029600.0
https://www.neurobopharma.com/

IPO

2016-08-05

Employees

5

Officers

CEO, President, Principal Executive & Director
Mr. Hyung-Heon Kim
CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Marshall H. Woodworth
Chief Scientific Officer
Dr. Mi-Kyung Kim
Senior Vice President of Clinical Operations
Mr. Robert Homolka

See Also

Discover More
What is the Intrinsic Value of one NRBO stock?

The intrinsic value of one NRBO stock under the Base Case scenario is 4.57 USD.

Is NRBO stock undervalued or overvalued?

Compared to the current market price of 3.45 USD, Neurobo Pharmaceuticals Inc is Undervalued by 25%.